Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title Date of Registrationsort icon State
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. 2010-12-29 Registered
14F7 MAb marked with Tc99 Phase II in breast tumors. 2010-12-29 Registered
T1h in severe psoriasis-expanded access program (PUCE) 2012-07-20 Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors 2013-06-19 Registered
EGF vaccine- Advanced Lung tumors 2013-06-20 Registered
Post EUA study of Itolizumab in COVID-19 21/03/2022 Registered outdated
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX 21/05/2021 Registered outdated
Nimotuzumab in COVID-19 21/05/2021 Registered
VSSPs in renal carcinoma. 21/06/2023 Registered
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II 22/04/2016 Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis 22/05/2015 Registered
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations 22/05/2021 Registered outdated
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant 22/09/2022 Registered
CIMAvax-EGF in patients at high risk of lung cancer 22/10/2020 Registered outdated
hR3 in metastatic or recurrent colorectal cancer 22/11/2013 Registered
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. 23/05/2014 Registered
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus 23/12/2016 Registered
Itolizumab Safety and Efficacy Study in Covid 19 26/03/2021 Registered
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. 26/05/2014 Registered
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer 28/11/2016 Registered